Long-form, data-driven studies on 1.6M+ filings across 43 markets. Comparative regulation, walk-forward backtests, profiles, market mechanics.
GSK’s August share-plan buys came as pharma traded unevenly, AstraZeneca stayed in focus, and GSK’s own setup kept improving.
Teleperformance insiders sold about EUR 3.9m in August. Read that cluster against AI-driven BPO pressure, CAC 40 strength, and TTEC's weaker print.
Tikehau Capital’s latest insider buy sits inside a 63-purchase cluster, but the real question is whether the sector backdrop and valuation can carry it.
Standard Chartered’s August selling cluster lands after a $1.71bn profit beat and a fresh buyback. Here is what the filings add, and what they do not.
Five insiders bought Black Diamond on August 14, as the stock pushed above its 200-day average and modular demand stayed constructive.
Boralex insiders bought after the Brookfield and La Caisse takeout. Here is what the cluster says, and why the delisting changes the read.
Two Kernaghan buys on August 14 put Black Diamond Group on the screen as TSX energy strength and oil above US$82 support the backdrop.
Edgewise CEO Kevin Koch sold EUR 785,042 in sell-to-cover filings on August 12, 2026. Read it against biotech strength, peers, and prior prints.
Matador Resources CEO Joseph Wm Foran bought 15,000 shares as oil stayed firm, Q2 beat guidance, and peers kept the Permian bid alive.
Venture Global’s Sarah Blake sold 1 million shares after a strong LNG run. We read the sale against Cheniere, guidance, and the sector backdrop.
Riskified’s CFO sold EUR 927,914 after a 22% revenue jump and a guidance raise. Read the filing against peers, valuation and the cluster.
Ligand CFO Octavio Espinoza sold EUR 8.0m after a 10b5-1 plan, while biotech stays firm and peers like RPRX frame the valuation debate.